Publicly Traded Gene Therapy CompaniesU.S. Exchanges
List of Publicly Traded Gene Therapy Companies Listed on Major U.S. Exchanges
The publicly traded companies on this list are engaged in gene therapy which uses genes in the attempt to treat or prevent a wide range of diseases.
Additional publicly traded biotech and pharmaceutical companies and categories can be accessed through the links below:
A comparison widget that shows trend, earnings per share (EPS), P/E ratio and beta for each of the companies on this list can be accessed through the link below.
Select the company’s link to access charts, news links and company website and social media information.
Applied Genetic Technologies Corporation (AGTC) (Treatments for rare eye diseases caused by mutated genes)
Audentes Therapeutics, Inc. (BOLD) (IPO July 20, 2016: biotech company focused on therapy treatments for rare diseases)
Avexis Inc. (AVXS) (IPO February 11, 2016: Gene therapy company with a focus on rare neurological genetic diseases)
Bluebird Bio, Inc. (BLUE) (Gene therapies for severe genetic and rare diseases)
Fibrocell Science Inc. (FCSC) (Cell and gene therapy company: rare and serious skin and connective tissue diseases)
Krystal Biotech, Inc. (KRYS) (IPO September 20, 2017; biotech company: treatments for dermatological diseases utilizing gene therapy)
Regenxbio Inc. (RGNX) (IPO in September 2015: In vivo gene therapy products designed to treat various diseases)
Rocket Pharmaceuticals, Inc. (RCKT) (Biotech company: gene therapies for rare diseases)
Spark Therapeutics, Inc. (ONCE) (Gene therapies: treatments for debilitating genetic diseases)
UniQure N.V. (QURE) (Netherlands: gene therapy)
Voyager Therapeutics, Inc. (VYGR) (IPO in November 2015: clinical stage gene therapy company: central nervous system)
Xenon Pharmaceuticals Inc. (XENE) (Canada, biopharmaceutical company: lipoprotein lipase deficiency)